Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly
about
Cost-effectiveness of Tdap vaccination of adults aged ≥65 years in the prevention of pertussis in the US: a dynamic model of disease transmission.Vaccination in the elderly: what can be recommended?Relationship between patient copayments in Medicare Part D and vaccination claim status for herpes zoster and tetanus-diphtheria-acellular pertussis.Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
P2860
Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly
@ast
Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly
@en
Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly
@nl
type
label
Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly
@ast
Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly
@en
Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly
@nl
prefLabel
Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly
@ast
Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly
@en
Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly
@nl
P2093
P2860
P50
P1433
P1476
Cost-effectiveness analysis of Tdap in the prevention of pertussis in the elderly
@en
P2093
Bhakti Arondekar
Cristina Masseria
Girishanthy Krishnarajah
Gregory Hill
Michelle Skornicki
Narin Pruttivarasin
P2860
P304
P356
10.1371/JOURNAL.PONE.0067260
P407
P577
2013-09-03T00:00:00Z